Euglycemic DKA in an Adolescent Treated With a Sodium-Glucose Cotransporter-2 Inhibitor
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a class of glucose-lowering medications that were recently approved for pediatric type 2 diabetes (T2D). A serious adverse effect of SGLT2i is euglycemic diabetic ketoacidosis (euDKA), a rare life-threatening metabolic emergency that was recognized after an increase in adult cases noted in postapproval safety surveillance programs. To our knowledge, SGLT2i-assoicated euDKA has not yet been described in youth with T2D since SGLT2i received pediatric approval in 2023. We report on a 17-year-old female patient with T2D on an SGLT2i who developed euDKA. She initially presented with vomiting that improved with antiemetics; however, she had persistent ketosis and developed significant acidosis, prompting diagnosis of euDKA. She was treated with intravenous insulin, dextrose-containing fluids, and electrolyte replacement with resolution of euDKA. This case highlights the challenges of recognizing SGLT2i-asosciated euDKA because of its rarity and the lack of hyperglycemia. As an increasing number of youth are started on SGLT2i, practitioners must be aware of the risk of SGLT2i-associated euDKA to allow for early recognition, adequate treatment, and prevention of serious complications.
Authors
- John T. Walker (ORCID: https://orcid.org/0000-0002-6552-5401)
- Karla F. Leavens (ORCID: https://orcid.org/0000-0001-9562-899X)
- Andrea True Kelly (ORCID: https://orcid.org/0000-0003-1724-9868)
- Patricia Y. Chu (ORCID: https://orcid.org/0000-0002-4633-1716)
Institutions
- Children's Hospital of Philadelphia (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- PEDIATRICS
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1542/peds.2026-077033
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00